Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy

Phase 2

Completed

Conditions: Extrahepatic Bile Duct Cancer
Gallbladder Cancer

Interventions: Drug: Gemcitabine
Drug: Cisplatin
Drug: Sorafenib

First Posted Date: 2009-06-12

Last Posted Date: 2016-02-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 39

Registration Number: NCT00919061

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer

Terminated

Conditions: Bladder Cancer

Interventions: Genetic: Blood draw

First Posted Date: 2009-06-11

Last Posted Date: 2015-03-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 12

Registration Number: NCT00918008

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
New York Presbyterian Hospital-Weill Medical College of Cornell University, New York, New York, United States

Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer

Phase 2

Completed

Conditions: Gastroesophageal Junction Cancer
Esophageal Cancer

Interventions: Drug: Sorafenib, administered orally
Procedure: CT/MRI

First Posted Date: 2009-06-10

Last Posted Date: 2019-03-27

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 35

Registration Number: NCT00917462

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma

Phase 1

Active, not recruiting

Conditions: Neuroblastoma

Interventions: Biological: adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH
Biological: oral β-glucan

First Posted Date: 2009-06-02

Last Posted Date: 2024-06-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 374

Registration Number: NCT00911560

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer

Phase 1

Active, not recruiting

Conditions: Adenocarcinoma
Prostate Cancer

Interventions: Radiation: Hypofractionated, image-guided, intensity-modulated external beam radiation

First Posted Date: 2009-06-01

Last Posted Date: 2023-09-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 120

Registration Number: NCT00911118

Locations: 🇺🇸
Memorial Sloan Kettering West Harrison, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States

and more 4 locations

Study of Radiation Exposure and Bilateral Breast Cancer

Active, not recruiting

Conditions: Breast Cancer

Interventions: Other: questionaire, blood or saliva sample

First Posted Date: 2009-05-18

Last Posted Date: 2024-07-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 1699

Registration Number: NCT00903591

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇨🇦
ONTARIO CANCER REGISTRY, Mount Sinai Hospital, Toronto, Toronto, Ontario, Canada
🇩🇰
Danish Cancer Society, København, Denmark

and more 3 locations

Controlled Trial Comparing Nomogram-based Versus Standard Allocation of Acute Normovolemic Hemodilution (ANH) During Hepatic Resection

Phase 3

Completed

Conditions: Liver Cancer

Interventions: Procedure: nomogram-based selection for acute normovolemic hemodilution
Procedure: standard selection for ANH based on a planned resection of 3 or more segments

First Posted Date: 2009-05-15

Last Posted Date: 2015-08-13

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 149

Registration Number: NCT00902343

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Genotype-Phenotype Urothelial Cancer Registry

Active, not recruiting

Conditions: Renal Pelvis Cancer
Ureter Cancer
Bladder Cancer
Urothelial Cancer

Interventions: Other: saliva sample, questionaire
Other: saliva sample and questionaire

First Posted Date: 2009-05-15

Last Posted Date: 2024-07-31

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 3519

Registration Number: NCT00902590

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Nassau, Uniondale, New York, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States

and more 1 locations

Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer

Active, not recruiting

Conditions: Breast Cancer

First Posted Date: 2009-05-12

Last Posted Date: 2024-11-11

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 269

Registration Number: NCT00897702

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth (Consent only), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Nassau (Consent only), Uniondale, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 4 locations

Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes

Phase 2

Completed

Conditions: Sarcoma
Leiomyosarcoma
Malignant Fibrous
Histiocytoma
Angiosarcoma

Interventions: Drug: gemcitabine
Drug: docetaxel
Drug: bevacizumab

First Posted Date: 2009-04-24

Last Posted Date: 2016-01-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 47

Registration Number: NCT00887809

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy